Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Study:

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Rationale:

n/a

Purpose:

Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Hematologic Malignancies
AML
Drug: CP-4055
Drug: CP-4055
Phase 1/Phase 2

Verified by Clavis Pharma September, 2013

Sponsored by: Clavis Pharma
Information provided by: Clavis Pharma
ClinicalTrials.gov identifier: NCT00405743

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Francis J Giles, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site